Vanda Pharmaceuticals
VNDA
153 hedge funds and large institutions have $369M invested in Vanda Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 39 increasing their positions, 64 reducing their positions, and 23 closing their positions.
909% more call options, than puts
Call options by funds: $10.5M | Put options by funds: $1.04M
65% more capital invested
Capital invested by funds: $225M → $369M (+$145M)
22% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 23
2% more funds holding
Funds holding: 150 → 153 (+3)
5.09% less ownership
Funds ownership: 75.97% → 70.89% (-5.1%)
39% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 64
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$11M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$3.3M |
| 3 |
EFMC
Empire Financial Management Company
New York
|
+$1.93M |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
+$1.85M |
| 5 |
Two Sigma Investments
New York
|
+$1.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$11.7M |
| 2 |
Millennium Management
New York
|
-$8.65M |
| 3 |
BlackRock
New York
|
-$6.3M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$2.9M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.45M |
VNDA Hedge Fund Activity: Q4 2025 in Review
153 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q4 2025, worth a combined $369M — up 65% from $225M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new VNDA positions and 23 closed out — a net gain of 5 holders — while 39 added to existing stakes and 64 trimmed.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $11M. The largest seller was Tang Capital Management, exiting entirely with an estimated $11.7M sold.
- 153 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q4 2025, up from 150 in Q3 2025.
- Funds reported $369M of Vanda Pharmaceuticals stock for Q4 2025, up 65% quarter-over-quarter.
- 28 funds opened new Vanda Pharmaceuticals positions in Q4 2025 and 23 closed out, a net change of +5 holders.
- The largest Vanda Pharmaceuticals buyer in Q4 2025 was AIGH Capital Management, an estimated $11M added.
- The largest Vanda Pharmaceuticals seller in Q4 2025 was Tang Capital Management, an estimated $11.7M sold.
Based on aggregated 13F filings for Q4 2025.